Werewolf Therapeutics Selected for Oral Presentation and to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting

Werewolf Therapeutics (HOWL) will give an oral presentation and present two posters at SITC’s annual meeting on November 4-8, 2026.

Rhea-AI Summary

Werewolf Therapeutics (HOWL) will give an oral presentation and present two posters at SITC’s annual meeting on November 4-8, 2026. The meeting takes place in Phoenix, Arizona.

The November 7 oral presentation covers a Phase 1/1b study of WTX-124, alone or with pembrolizumab, in adults with relapsed or refractory, advanced or metastatic, immunotherapy-sensitive solid tumors. Justin Moser of HonorHealth Research Institute will present. The listed poster covers a Phase 1b/2 study of WTX-330 in patients with relapsed or refractory solid tumors, also on November 7.

Argus Oct 30 session 15 alerts

-10.35% close to close 1.1x rel. volume Open Argus

Details

Market move: HOWL -10.35% in the Oct 30 session. SITC 2026 presentations

-7.6% Trough in 5 hr 42 min

$51.03M Mkt Cap at Peak Alert

On Oct 30, the day this news came out, HOWL closed 10.35% below the previous close. Argus tracked a trough of -7.6% from its starting point during tracking. Our momentum scanner recorded 15 alerts for this stock that day.

Data tracked by StockTitan Argus for the Oct 30 session.

Key Terms

il-2, il-12, prodrug

3 terms

il-2 medical

"the tumor-activated IL-2 prodrug WTX-124"

Interleukin-2 (IL-2) is a small protein the body uses as a messenger to tell immune cells when to grow and act, like a coach sending signals to players on a team. For investors, IL-2 matters because drugs that boost, mimic, or block its activity can change how well immune therapies work and what side effects they cause, affecting clinical trial success, regulatory approval prospects, and commercial value.

il-12 medical

"the tumor-activated IL-12 prodrug WTX-330"

Interleukin-12 (IL-12) is a small signaling protein made by immune cells that helps turn on and direct the body’s defense system, especially the types of cells that hunt infections and cancer. For investors, IL-12 matters because drugs that boost or block it are promising targets in cancer and inflammatory disease research; changes in clinical trial results, safety signals, or regulatory views about IL-12-based therapies can strongly affect a biotech’s value, much like a thermostat that changes how a whole heating system behaves.

prodrug medical

"the tumor-activated IL-2 prodrug WTX-124"

A prodrug is an inactive or less-active compound that is designed to be converted into an active drug inside the body, like a packaged meal that needs heating before it's ready to eat. For investors, prodrugs matter because this design can improve how a medicine is absorbed, reduce side effects, extend patent protection, or enable new dosing forms — all factors that can affect a drug's regulatory path, marketability, and commercial value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been selected for an oral presentation and will present two posters at the upcoming Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Oral Presentation Details

Title: A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors
Abstract Number: 1189
Presenter: Justin Moser, M.D., HonorHealth Research Institute
Presentation Time: Saturday, November 7, 2026; 2:30-2:45 p.m. MT
Location: North Building - 300 Level – Halls BC
Session 205: Clinical Oral Abstract Session 2, 1:30-3:00 p.m. MT
Session Schedule: https://www.sitcancer.org/2026/schedule/sitc-2026-schedule#session-1643

Details for the poster presentation is as follows:

Title: A Phase 1b/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed/refractory solid tumors
Abstract Number: 494
Session Date and Time: Saturday, November 7, 2026; 9 a.m.–8:30 p.m. MT
Location: North Building -Lower Level – Exhibition Halls 4-6

About Werewolf Therapeutics
Werewolf Therapeutics is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. Werewolf Therapeutics has designed conditionally activated INDUKINE™ molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf Therapeutics’ clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 and Interleukin-12 INDUKINE molecules, respectively, for the treatment of solid tumors.

WEREWOLF^®, the WEREWOLF logo, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.

Company Contact:
Jonathan Owen
SVP, General Counsel and Secretary
Werewolf Therapeutics
jowen@werewolftx.com